334-42-9

Basic information

• Product Name: 1-bromo-7-fluoroheptane
• Synonyms: 1-bromo-7-fluoroheptane;1-fluoro-7-broMoheptane
• CAS NO: 334-42-9
• Molecular Formula: C₇H₁₄BrF
• Molecular Weight: 197.0884632
• EINECS: -0
• Mol File: 334-42-9.mol

Chemical Properties

• Boiling Point: 202.6 °C at 760 mmHg
• Flash Point: 78.9 °C
• Appearance: /
• Density: 1.2240 (rough estimate)
• Refractive Index: 1.4463
• CAS DataBase Reference: 1-bromo-7-fluoroheptane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-bromo-7-fluoroheptane(334-42-9)
• EPA Substance Registry System: 1-bromo-7-fluoroheptane(334-42-9)

Safety Data

• Hazardous Substances Data: 334-42-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-bromo-7-fluoroheptane is used as a synthetic intermediate for the production of various pharmaceuticals. Its unique halogenated structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 1-bromo-7-fluoroheptane serves as a key intermediate in the synthesis of pesticides and other agricultural chemicals. Its ability to be incorporated into complex molecular structures makes it valuable for enhancing the effectiveness of these products.
Used in Organic Synthesis:
1-bromo-7-fluoroheptane is utilized as a reagent in organic synthesis, facilitating various chemical reactions and transformations. Its presence can influence the outcome of these reactions, making it an important component in the synthesis of a multitude of organic compounds.
Used in Chemical Production:
As a building block, 1-bromo-7-fluoroheptane is employed in the manufacturing process of a variety of chemicals. Its structural properties enable it to be a fundamental component in the assembly of different chemical entities, broadening its applications across various industries.
It is crucial to handle 1-bromo-7-fluoroheptane with care, as it is classified as a hazardous material. Exposure may result in irritation to the skin, eyes, and respiratory system, necessitating proper safety measures during its use and storage.

Upstream product

• 408-16-2 7-fluoro-heptan-1-ol 
• 10160-24-4 7-bromoheptyl alcohol 
• 2695-48-9 8-Bromo-1-octene 
• 75-09-2 dichloromethane 

Downstream Products

• 463-19-4 9-Fluor-non-1-in 
• 374109-41-8 (2-{2-[4-(7-fluoro-heptyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl]-ethoxy}-phenyl)-acetic acid methyl ester 

Relevant articles and documents

Benzoxazinones as PPARγ Agonists. 2. SAR of the Amide Substituent and In Vivo Results in a Type 2 Diabetes Model

A series of benzoxazinones has been synthesized and tested for PPARγ agonist activity. Synthetic approaches were developed to provide either racemic or chiral compounds. In vitro functional potency could be measured through induction of the aP2 gene, a target of PPARγ. These studies revealed that compounds with large aliphatic chains at the nitrogen of the benzoxazinone were the most potent. Substitution of the chain was tolerated and in many cases enhanced the in vitro potency of the compound. Select compounds were further tested for metabolic stability, oral bioavailability in rats, and efficacy in db/db mice after 11 days of dosing. In vivo analysis with 13 and 57 demonstrated that the series has potential for the treatment of type 2 diabetes.

Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: Synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential

A series of ibutilide analogues with fluorine substituents on the heptyl side chain was prepared and evaluated for class III antiarrhythmic activity, metabolic stability, and proarrhythmic potential. It was found that fluorine substituents stabilized the side chain to metabolic oxidation. Many of the compounds also retained the ability to increase the refractoriness of cardiac tissue at both slow and fast pacing rates. The potential for producing polymorphic ventricular tachycardia in the rabbit model was dependent on the chirality of the benzylic carbon. The S-enantiomers generally had less proarrhythmic activity than the corresponding racemates. One compound from this series (45E, trecetilide fumarate) had excellent antiarrhythmic activity and metabolic stability and was devoid of proarrhythmic activity in the rabbit model. It was chosen for further development.

Antiarrhythmic (S)-enantiomers of methanesulfonamides

Compounds of formula (I) and pharmacologically acceptable salts thereof wherein: n is 1 to 3, R is an alkyl, R1 is hydrogen or alkyl, R2 is alkyl, R3 is an alkyl; b) alkyl substituted with an aryl, heteroaryl or cycloalkyl

Antiarrhythmic methanesulfonamides

Methanesulfonamides are structurally depicted by Formula I' STR1 or its pharmacologically acceptable salts where R3 is a C1-7 alkyl substituted with C3-7 cycloalkyl, or a C1-10 alkyl substituted with one to eigh